Indirect Treatment Comparison (ITC) of Inotuzumab Ozogamicin (InO) and Blinatumomab (Blina) for Relapsed or Refractory (RR) Acute Lymphoblastic Leukemia (ALL)

被引：0
|
作者：
Stelljes, Matthias
Su, Yun
Fahrbach, Kyle
Vandendries, Erik
Page, Veronique
Onyekwere, Uchenna
Wang, Yunyang
Cappelleri, Joseph C.
Proskorovsky, Irina
机构：
来源：
BLOOD | 2017年 / 130卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
2558
引用
收藏
页数：3
相关论文
共 50 条
  • [1] Indirect Treatment Comparison of Inotuzumab Ozogamicin Versus Blinatumomab for Relapsed or Refractory Acute Lymphoblastic Leukemia
    Irina Proskorovsky
    Yun Su
    Kyle Fahrbach
    Erik Vandendries
    Véronique Pagé
    Uchenna Onyekwere
    Yunyang Wang
    Joseph C. Cappelleri
    Matthias Stelljes
    Advances in Therapy, 2019, 36 : 2147 - 2160
  • [2] Indirect Treatment Comparison of Inotuzumab Ozogamicin Versus Blinatumomab for Relapsed or Refractory Acute Lymphoblastic Leukemia
    Proskorovsky, Irina
    Su, Yun
    Fahrbach, Kyle
    Vandendries, Erik
    Page, Veronique
    Onyekwere, Uchenna
    Wang, Yunyang
    Cappelleri, Joseph C.
    Stelljes, Matthias
    ADVANCES IN THERAPY, 2019, 36 (08) : 2147 - 2160
  • [3] Response to Letter to the Editor Regarding: Indirect Treatment Comparison of Inotuzumab Ozogamicin versus Blinatumomab for Relapsed or Refractory Acute Lymphoblastic Leukemia
    Proskorovsky, Irina
    Vandendries, Erik
    Page, Veronique
    Cappelleri, Joseph C.
    Stelljes, Matthias
    ADVANCES IN THERAPY, 2020, 37 (02) : 958 - 962
  • [4] Response to Letter to the Editor Regarding: Indirect Treatment Comparison of Inotuzumab Ozogamicin versus Blinatumomab for Relapsed or Refractory Acute Lymphoblastic Leukemia
    Irina Proskorovsky
    Erik Vandendries
    Véronique Pagé
    Joseph C. Cappelleri
    Matthias Stelljes
    Advances in Therapy, 2020, 37 : 958 - 962
  • [5] Matching-Adjusted Indirect Comparison of Blinatumomab vs. Inotuzumab Ozogamicin for Adults with Relapsed/Refractory Acute Lymphoblastic Leukemia
    Jinlin Song
    Qiufei Ma
    Wei Gao
    Ze Cong
    Jipan Xie
    Zachary Zimmerman
    Laura Belton
    Janet Franklin
    Stephen Palmer
    Advances in Therapy, 2019, 36 : 950 - 961
  • [6] Matching-Adjusted Indirect Comparison of Blinatumomab vs. Inotuzumab Ozogamicin for Adults with Relapsed/Refractory Acute Lymphoblastic Leukemia
    Song, Jinlin
    Ma, Qiufei
    Gao, Wei
    Cong, Ze
    Xie, Jipan
    Zimmerman, Zachary
    Belton, Laura
    Franklin, Janet
    Palmer, Stephen
    ADVANCES IN THERAPY, 2019, 36 (04) : 950 - 961
  • [7] Role of inotuzumab ozogamicin in the treatment of relapsed/refractory acute lymphoblastic leukemia
    George, Binsah
    Kantarjian, Hagop
    Jabbour, Elias
    Jain, Nitin
    IMMUNOTHERAPY, 2016, 8 (02) : 135 - 143
  • [8] Blinatumomab and Inotuzumab Ozogamicin Sequential Use for the Treatment of Relapsed/Refractory Acute Lymphoblastic Leukemia: A Real-Life Campus All Study
    Fracchiolla, Nicola Stefano
    Sciume, Mariarita
    Papayannidis, Cristina
    Vitale, Antonella
    Chiaretti, Sabina
    Annunziata, Mario
    Giglio, Fabio
    Salutari, Prassede
    Forghieri, Fabio
    Lazzarotto, Davide
    Lunghi, Monia
    Imovilli, Annalisa
    Scappini, Barbara
    Bonifacio, Massimiliano
    Dargenio, Michelina
    Gurrieri, Carmela
    Todisco, Elisabetta
    Defina, Marzia
    Del Principe, Maria Ilaria
    Zappasodi, Patrizia
    Cerrano, Marco
    Santoro, Lidia
    Tagliaferri, Elena
    Barozzi, Enrico
    De Roberto, Pasquale
    Canzi, Marta
    Buzzatti, Elisa
    Sartor, Chiara
    Passamonti, Francesco
    Foa, Robin
    Curti, Antonio
    Wirth, Thomas
    CANCERS, 2023, 15 (18)
  • [9] Phase II trial of mini-hyper-CVD-inotuzumab (InO) followed by blinatumomab (blina) consolidation in patients with relapsed/refractory (R/R) acute lymphoblastic leukemia (ALL)
    Nasnas, Cedric Christophe
    Jabbour, Elias
    Haddad, Fadi
    Short, Nicholas James
    Macaron, Walid
    Zoghbi, Marianne
    Nasr, Lewis Fady
    Jain, Nitin
    Almanza, Emmanuel
    Sasaki, Koji
    Ravandi, Farhad
    Kebriaei, Partow
    Huang, Xuelin
    Garcia-Manero, Guillermo
    Kadia, Tapan M.
    Wang, Sa A.
    Jacob, Jovitta
    Garris, Rebecca
    O'Brien, Susan M.
    Kantarjian, Hagop M.
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [10] Inotuzumab ozogamicin in the treatment of relapsed/refractory acute B cell lymphoblastic leukemia
    Uy, Natalie
    Nadeau, Michelle
    Stahl, Maximilian
    Zeidan, Amer M.
    JOURNAL OF BLOOD MEDICINE, 2018, 9 : 67 - 74
12345